Peter Garcia
2021 - ALX ONCOLOGY HOLDINGS
In 2021, Peter Garcia earned a total compensation of $4.8M as Chief Financial Officer at ALX ONCOLOGY HOLDINGS.
Compensation breakdown
| Non-Equity Incentive Plan | $181,280 |
|---|---|
| Option Awards | $4,116,990 |
| Salary | $453,200 |
| Total | $4,751,470 |
Garcia received $4.1M in option awards, accounting for 87% of the total pay in 2021.
Garcia also received $181.3K in non-equity incentive plan and $453.2K in salary.
Rankings
In 2021, Peter Garcia's compensation ranked 2,773rd out of 12,415 executives tracked by ExecPay. In other words, Garcia earned more than 77.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,773 out of 12,415 | 78th |
Division Manufacturing | 1,096 out of 5,508 | 80th |
Major group Chemicals And Allied Products | 432 out of 2,378 | 82nd |
Industry group Drugs | 377 out of 2,099 | 82nd |
Industry Pharmaceutical Preparations | 253 out of 1,549 | 84th |
Source: SEC filing on April 24, 2023.
Garcia's colleagues
We found two more compensation records of executives who worked with Peter Garcia at ALX ONCOLOGY HOLDINGS in 2021.
News
ALX ONCOLOGY HOLDINGS CEO Jason Lettmann receives $4.9M in 2023
April 22, 2024
ALX ONCOLOGY HOLDINGS CEO Jaume Pons' 2022 pay falls 63% to $3.7M
April 24, 2023
PDL BioPharma CEO Dominique Monnet's 2019 pay jumps 168% to $6.7M
July 7, 2020
PDL BioPharma CEO John McLaughlin's 2018 pay rises 20% to $4.1M
April 30, 2019